Will Amgen’s migraine win and 5th thumbs-up for Prolia drive enough growth? Nope, says analyst

From the looks of it, Amgen is having a bang-up week. It won FDA approval for its highly anticipated migraine drug, Aimovig, Thursday, and yesterday it racked up its fifth nod for the bone drug Prolia. Growth-hungry investors have pushed Amgen’s stock up 3% to $176.47 in the past seven days.